Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03997123
What this trial is testing

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Who this might be right for
Triple Negative Breast Neoplasms
AstraZeneca 923
Testing effectiveness (Phase 2)Study completedNCT01349959
What this trial is testing

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Who this might be right for
Male Breast CarcinomaRecurrent Breast CarcinomaStage IIIC Breast Cancer AJCC v7+2 more
National Cancer Institute (NCI) 58
Not applicableLooking for participantsNCT07808086
What this trial is testing

Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Istituti Clinici Scientifici Maugeri SpA 30
Early research (Phase 1)Study completedNCT04664829
What this trial is testing

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Who this might be right for
Metastatic Triple-Negative Breast Carcinoma
National Cancer Centre, Singapore 12
Testing effectiveness (Phase 2)Looking for participantsNCT06165900
What this trial is testing

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Who this might be right for
Stereotactic RadiotherapyImmunotherapyBreast Cancer
Shengjing Hospital 136
Testing effectiveness (Phase 2)Study completedNCT03167619
What this trial is testing

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Who this might be right for
Triple Negative Breast Cancer
Duke University 45
Early research (Phase 1)Ended earlyNCT04099277
What this trial is testing

LY3435151 in Participants With Solid Tumors

Who this might be right for
Solid TumorTriple-negative Breast CancerGastric Adenocarcinoma+6 more
Eli Lilly and Company 2
Testing effectiveness (Phase 2)UnknownNCT04517292
What this trial is testing

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
Fudan University 160
Not applicableActive Not RecruitingNCT07046195
What this trial is testing

Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer

Who this might be right for
Hypofractionated RadiotherapyTriple Negative Breast Cancer (TNBC)Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 250
Testing effectiveness (Phase 2)Study completedNCT02001519
What this trial is testing

Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Asan Medical Center 88
Very early researchStudy completedNCT06273852
What this trial is testing

The Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer
Pure Biologics S.A. 8
Very early researchStudy completedNCT04674306
What this trial is testing

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

Who this might be right for
Pathologic Stage IIA-IIIC Triple-Negative Breast CancerTNBC - Triple-Negative Breast CancerResidual Disease
George T. Budd 35
Testing effectiveness (Phase 2)Looking for participantsNCT06189209
What this trial is testing

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Rhizen Pharmaceuticals SA 40
Early research (Phase 1)Study completedNCT03945604
What this trial is testing

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Who this might be right for
Triple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 32
Not applicableEnded earlyNCT04549584
What this trial is testing

Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer

Who this might be right for
Metaplastic Breast Carcinoma
Seoul National University Hospital 3
Testing effectiveness (Phase 2)Study completedNCT04877821
What this trial is testing

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Who this might be right for
Triple Negative Breast Cancer
Guangdong Provincial People's Hospital 29
Not applicableUnknownNCT03617341
What this trial is testing

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 PositiveTriple Negative Breast Cancer
Yonsei University 200
Large-scale testing (Phase 3)Active Not RecruitingNCT04296175
What this trial is testing

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Who this might be right for
Triple-negative Breast Cancer
Fudan University 808
Early research (Phase 1)Active Not RecruitingNCT05783622
What this trial is testing

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more
Janux Therapeutics 130
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Next Page